Alirocumab: Difference between revisions
Sergekorjian (talk | contribs) |
Sergekorjian (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Properties== | ==Properties== | ||
Alirocumab is a human [[monoclonal antibody]] that binds proprotein convertase subtilisin/kexin type 9 ([[PCSK9]]). [[PCSK9]] is a protein that attaches to surface [[LDL]] receptors and triggers their degradation. This reduces the ability of hepatocytes to uptake LDL cholesterol and subsequently leads to increased levels of circulating LDL. By binding PCSK9, alirocumab inhibits LDL receptor destruction and increases the endocytosis of LDL from the circulation. Pre-clinical studies, and early clinical trials have shown the efficacy and safety of alirocumab in decreasing [[LDL]] [[cholesterol]] as an add-on agent or as monotherapy. | |||
==Major Trials== | ==Major Trials== | ||
Revision as of 13:31, 19 March 2015
For a review of all PCSK9 inhibitors please click here
|
WikiDoc Resources for Alirocumab |
|
Articles |
|---|
|
Most recent articles on Alirocumab |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Alirocumab at Clinical Trials.gov Clinical Trials on Alirocumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Alirocumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Alirocumab Discussion groups on Alirocumab Patient Handouts on Alirocumab Directions to Hospitals Treating Alirocumab Risk calculators and risk factors for Alirocumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Alirocumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Alirocumab (REGN727 and SAR236553) is an investigational human monoclonal antibody that inhibits PCSK9 for the treatment of hypercholesterolemia.
Properties
Alirocumab is a human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that attaches to surface LDL receptors and triggers their degradation. This reduces the ability of hepatocytes to uptake LDL cholesterol and subsequently leads to increased levels of circulating LDL. By binding PCSK9, alirocumab inhibits LDL receptor destruction and increases the endocytosis of LDL from the circulation. Pre-clinical studies, and early clinical trials have shown the efficacy and safety of alirocumab in decreasing LDL cholesterol as an add-on agent or as monotherapy.